All In Biotech

Drug Trial Radar · NCT05133297

The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis

A Phase 2A, Randomized, Double-blind, Double-dummy, Tofacitinib-parallel-group Study to Evaluate the Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Methotrexate.

Last checked: Nov 19, 2026Latest source record: Sep 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 101 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

101

Actual

Start

Feb 16, 2022

Primary completion

Dec 19, 2022

Study completion May 30, 2023

Sponsor

Sponsor type
Industry
First posted
Nov 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, double-dummy, tofacitinib-parallel-group, phase 2A study to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subject who had an inadequate response or intolerance to methotrexate.

Conditions

  • Rheumatoid Arthritis

Interventions

  • TLL-018Drug

    Oral tablets administered at dose1 BID daily for 24 weeks.

  • TLL-018Drug

    Oral tablets administered at dose2 BID daily for 24 weeks.

  • TLL-018Drug

    Oral tablets administered at dose3 BID daily for 24 weeks.

  • TofacitinibDrug

    Oral tablets administered at 5 mg BID daily for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants American College of Rheumatology 50% (ACR50) Response at Week 12Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.